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Other Specific Nephropathies S61Results: Eighteen patients were enrolled in the study; 9 patients had car-
diac involvement. The overall hematologic response rate was 94.4% (17/
18), including 13 patients (72.2%) with complete response, 4 patients
(22.2%) with very good partial response. The organ response rate was
72.2%. The organ response was reached in 13 patients of the 18 patients
with renal involvement and 7 of the 9 patients with cardiac involvement.
Peripheral neuropathy and infection were the common adverse events,
and 4 patients have been discontinued bortezomib for neuropathy. No
death occurred. After a median follow up of 24 months, the overall survival
was 100%, and the estimated progression free survival was 91% at 48
months.
Conclusion: Our preliminary data suggest that incorporating bortezomib into
induction, conditioning and consolidation with ASCT yielded a high rate of
hematologic response with tolerable toxicity.
(ClinicalTrial.gov Identifier: NCT01273844)http://dx.doi.org/10.1016/j.hkjn.2015.09.0090062
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Table 1. Demographics and Laboratory Evaluation for Patients with Monoclona
Patient No. 1 2 3
Sex M M M
Age (y) 48 60 54
Duration of renal disease (m) 21 36 4
Hypertension Yes Yes Yes
Proteinuria (g/d) 1.0 3.0 4.5
Hematuria (104/ml) 30 3 36
Alb (g/l) 42.0 24.0 33.9
Glo (g/l) 22.7 17.8 24.9
SCr (mg/dl) 0.9 2.7 0.8
Hb (g/dL) 12.9 7.5 14.2
C3 (g/L) 1.0 0.6 0.4
C4 (g/L) 0.3 0.1 0.1
C3NeF Negative Negative Negat
AntiFH antibody Negative Negative Negat
Factor H Normal ND Norm
k:l Ratio 0.8 1.4 1.0
Immunofixation (serum) IgAl IgGl IgGk
Plasma cells in bone marrow ND Normal Norm
Alb Z albumin; SCr Z serum creatinine; Hb Z hemoglobin; M Z male; F Z fe
Reference ranges are as follows: proteinuria, 0.4 g/d; Alb, 35.0e55.0 g/L; SCr
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Table 2. Demographics and Laboratory Evaluation for Patients without Monoclo
Patient No. 1 2 3 4
Age (y) 77 27 41 56
Sex M F F M
Hypertension Yes No Yes Yes
Proteinuria (g/d) 2.4 0.9 4.3 1.6
Hematuria (104/ml) 75 17 75 76
Alb (g/l) 33.5 39.3 21.8 43.3
SCr (mg/dl) 1.9 0.5 0.7 0.7
Hb (g/dL) 9.9 12.3 11.5 12.8
C3 (g/L) 0.9 0.1 0.1 0.6
C4 (g/L) 0.2 0.1 0.1 0.2
C3NeF Negative Negative Negative Negative
AntiFH antibody Negative Negative Negative Negative
Factor H Normal Normal Normal Normal
Alb Z albumin; SCr Z serum creatinine; Hb Z hemoglobin; M Z male; F Z fe
Reference ranges are as follows: proteinuria, 0.4 g/d; Alb, 35e55 g/L; SCr, 0Nephrology, Jinling Hospital, Nanjing University School of Medicine,
Nanjing, Jiangsu, China
Background: C3 glomerulonephritis (GN) has been a recently introduced GN
resulting from dysregulation of the alternative pathway (AP) of complement.
Monoclonal gammopathy is an important secondary cause of dysregulation of
the AP, which has been a research hotspot at present.
Methods: Between March 2004 to April 2015, in a total of 16 patients with C3
GN, 7 patients had evidence of monoclonal immunoglobulin in serum. Clin-
ical features, hematologic findings, kidney biopsy, complement pathway ab-
normalities, treatment, and follow-up were collected.
Results: Patients with monoclonal immunoglobulin were 5 males and 2 fe-
males, 44e65 (mean, 55.4) years old. All of them had proteinuria ranging
from 1.04e7.34 g/d. Microscopic hematuria was observed in 6 patients,
elevated serum creatine (SCr) in 3 patients, hypertension in 6 patients, low
serum complement C3 in 4 patients, and complement C4 was normal in all pa-
tients (Table 1). No abnormalities were found for serum C3 nephritic factors
(C3NeFs), factor H and anti-factor H antibody. The most common monoclonal
gammopathy was IgGl (3 patients). Other gammopathies included IgGk (2 pa-
tients), IgAl (one patient), and light chain k (one patient). Elevated plasma
cells were observed in 2 of 6 patients (Table 1). Membranoproliferative GN
was present in all patients (Table 2). Two patients with abnormal plasma cells
received thalidomide plus dexamethasone, of whom one achieved long-time
complete remission in renal disease, and one had progression in kidney dis-
ease. The other 5 patients received either Tripterygium wilfordii and/or glu-
cocorticosteroid, of whom one was lost to follow-up, 4 had improvement in
urine analysis, and 3 had stable renal function (Table 3).l Gammopathy.
4 5 6 7
M M F F
65 44 64 53
42 67 3 60
No Yes Yes Yes
1.2 3.7 1.7 7.3
18 75 1000 78
35.5 24.6 30.0 21.4
19.9 17.9 47.0 23.2
0.9 0.7 2.4 1.7
5.9 15.5 6.0 8.4
0.8 0.9 0.6 0.4
0.2 0.2 0.1 0.1
ive Negative Negative Negative Negative
ive Negative Negative Negative Negative
al Normal Normal Normal Normal
1.5 1.9 0.2 3.5
IgGl LCk IgGl IgGk
al Normal 6.5% 45.5% Normal
male; ND Z none detected.
, 0.51e1.24 mg/dl; Hb, 12.0e17.5 g/dl; C3, 0.8e1.8 g/L; C4, 0.1e0.4 g/L.
nal Gammopathy.
5 6 7 8 9
70 39 42 13 19
M F F M F
Yes Yes Yes No No
4.0 2.0 0.9 0.6 1.0
256 11 2 250 3
28.1 37.1 35.9 45.3 45.8
1.8 0.9 0.8 0.6 0.6
6.4 13.5 12.5 12.7 13.2
1.5 0.7 0.8 0.5 0.7
0.3 0.2 0.2 0.1 0.1
Negative Negative Negative Negative Negative
Negative Negative Negative Negative Negative
Normal Normal Normal Normal Normal
male.
.51e1.24 mg/dl; Hb, 12.0e17.5 g/dl; C3, 0.8e1.8 g/L; C4, 0.1e0.4 g/L.
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Table 3. Kidney Biopsy Findings of Patients with Monoclonal Gammopathy.
Patient
No.
Pattern
of Injury
%Globally
Sclerosed Glomerull
%Crescent %Interstitial
Fibrosis
IF Microscopy EM
1 MPGN 5.4% 2.7% 20.0% C3 2 + (CW) Endotheliocyte injuried，subendothelial
expansion with fluffy material
2 MPGN 55.0% 0.0% 25.0% C3 2 + (CW and MES) electron-dense deposits in MES and SU
3 MPGN 17.6% 0.0% 20.0% C3 2 + (CW and MES) electron-dense deposits in MES
4 MPGN 0.0% 0.0% 25.0% C3 2 + (CW and MES) subendothelial expansion with fluffy material
5 MPGN 14.9% 3.7% 10.0% C3 2 + (CW) electron-dense deposits in MES and SU
6 MPGN 9.1% 0.0% 5.0% C3 2 + (CW and MES) electron-dense deposits in MES, SU and SE
7 MPGN 28.6% 0.0% 4.0%% C3 3 + (CW and MES)/IgG, IgM (trace) electron-dense deposits in MES, SU
MPGN Z membranoproliferative glomerulonephritis; CW Z capillary wall; MES Z mesangial; SE Z subepithelial; SU Z subendothelial.
S62 Other Specific NephropathiesConclusion: Monoclonal gammopathy was a predominant cause of
C3 GN in the older patients. Pattern of pathological injury was membra-
noproliferative. Immunodepressive therapy may be effective,
but the key point of therapy should be targeting monoclonal
gammopathy.http://dx.doi.org/10.1016/j.hkjn.2015.09.0100066
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Background: Higher glomerular PLA2R-antigen deposit (GAg) rates
compared with serum phospholipase A2 receptor-antibody (SAb) positive
rates were reported. However, the exact roles played by these two bio-
markers remain unknown.
Methods: A total of 572 patients diagnosed with IMN were included. Both SAb
and GAg were detected. Fifty-two IMN patients received repeat renal biopsy
were included.
Results: 572 patients, 401 (70.1%) were SAb positive (SAb+) while 171
(29.9%) were SAb negative (SAb-). In SAb+ patients, the glomerular
PLA2R-antigen deposition (GAg+) was observed in 99.1% (397/401). Inter-
estingly, the GAg+ was observed in 68.4% (117/171) Sab patients. Pa-
tients with SAb manifested more severe proteinuria (3.9 g/24 hours
vs. 2.8 g/24 hours, P < 0.001) and lower eGFR (104 ml/min/1.73 m2
vs. 110 ml/min/1.73 m2, P Z 0.002) than patients without SAb. Further
comparison between SAb+/GAg+ and SAb-/GAg+ showed a similar profile.
Patients with SAb+/GAg+ also showed lower chance of proteinuria
remission and higher chance of renal function decline in the follow up
when compared to patients with SAb-/GAg+. Changes of SAb and
GAg were observed in patients with repeat renal biopsy, in 11 patients
the SAb+ turned into SAb-, among them 1 patient failed to achieve
remission, 7 patients achieved remission and 4 remitted during the in-
terval but relapsed at the time of repeat biopsy. While the GAg+
turned into GAg- in only 3 patients, all achieved remission at the repeat
biopsy. The proportion of GAg disappearance was lower than SAb
(P Z 0.016).
Conclusion: The GAg deposit can be detected in a large proportion of SAb
negative patients, which can be explained by the lag of GAg disappearance
in the follow up. SAb was more tightly correlated to disease activity, treat-
ment response and prognosis than GAg. We recommend adopting GAg depo-
sit detection as a supplement to SAb in IMN diagnosis and continuing to
monitor SAb during follow-up.http://dx.doi.org/10.1016/j.hkjn.2015.09.0110074
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Background: Preeclampsia (PE) is a life-threatening hypertensive disorder of
pregnancy. Soluble fms-like tyrosine kinase 1 (sFlt-1) is elevated and known
to contribute to PE. However, molecular basis underlying its up-regulation in
PE remain unclear.
Methods and Results: By using immunohistochemistry and western blot, we
demonstrated hypoxia inducible factor-1a (HIF-1a), an important transcrip-
tional factor, andU2 small nuclear ribonucleoprotein auxiliary factor 65-kilodal-
ton subunit (U2AF65), a key factor involved in alternative splicing, are
significantly increased in the placental tissue fromPEpatients.Using two animal
models of PE including angiotensin II type 1 receptor agonistic autoantibody
(AT1-AA) and LIGHT (a TNF-a superfamily member)-induced PE mouse model
coupled with in vivo nanoliposome-delivery system to specifically knockdown
HIF-1a and U2AF65, we found that knockdown of HIF-1a or U2AF65 siRNA signif-
icantly attenuated AT1-AA-induced hypertension (HIF-1a siRNA: 137 4mmHg;
U2AF65 siRNA: 140 5 mmHg vs. AT1-AA group 164 3 mmHg, p < 0.05), pro-
teinuria (HIF-1a siRNA: 41.6 3.2 mg/mg, U2AF65 siRNA: 34.9 5.3 mg/mg vs.
AT1-AA group 85.9 4.8 mg albumin/mg creatinine, p < 0.05) and circulating
sFlt-1 level. Similarly, we found thatHIF-1a andU2AF65 knockdown significantly
reduced sFlt-1 levels, hypertension and proteinuria in LIGHT-infused pregnant
mice. Finally, using splice-specific PCR assay, we found that knockdown HIF-
1a significantly reduced total Flt-1 mRNA level in the placentas of both AT1-AA
and LIGHT-infused pregnant mice but no effect on the ratio of sFlt-1/ Flt-1. In
contrast, U2AF65 knock down significantly reduced the ratio of sFlt-1/ Flt-1
without an effect on total Flt-1 mRNA level in these two PE mouse models.
Conclusion: Overall, we have revealed two molecular basis underlying sFlt-1
inductions in PE: (1) elevated HIF-1a directly increases sFlt-1 levels under
transcriptional levels; (2) elevated U2AF65 enhances alternative splicing to
increase sFlt-1 levels.http://dx.doi.org/10.1016/j.hkjn.2015.09.0120078
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Objective: Long non-coding RNAs (lncRNAs) exert pathophysiologic functions in
many diseases. By using RNA sequencing,we recently found that lncRNA_5318 is
